SoftBank CEO Masayoshi Son looking for ‘strategic alliance’ amongst chipmaker Arm and Samsung

SoftBank CEO Masayoshi Son looking for ‘strategic alliance’ amongst chipmaker Arm and Samsung


Masayoshi Son, CEO of SoftBank, has been weighing up a variety of selections for chipmaker Arm soon after Nvidia walked absent from obtaining the firm.

Alessandro Di Ciommo | Nurphoto | Getty Images

SoftBank CEO Masayoshi Son stated he is seeking a “strategic alliance” among chipmaker Arm, which is owned by the Japanese huge, and South Korean tech conglomerate Samsung.

“I intend to take a look at Korea. I am hunting ahead to going to Korea for the initially time in a few many years. I’d like to speak with Samsung about a strategic alliance with Arm,” Son said in a assertion.

There ended up no further more facts provided by SoftBank on what a strategic alliance would entail, but it could mark a large shift in strategy for Son and his vision for Arm.

Samsung declined to remark when contacted by CNBC.

SoftBank acquired U.K.-headquartered Arm, a single of the world’s most significant chipmakers, in 2016 and Son has since claimed it is essential for the company’s very long-phrase vision as more and much more units become world wide web connected.

Given that then, SoftBank tried out to promote arm to chipmaker Nvidia but the deal fell by in February.

Son is now pushing toward a public listing for Arm, ideally in New York. But the U.K. federal government would like Arm to checklist in London. SoftBank wishes to continue to keep a greater part stake in Arm adhering to an first community giving.

Samsung’s Vice Chairman Lee Jae-yong said Wednesday he strategies to fulfill Son when he visits South Korea, in accordance to a report by The Korea Herald.

Lee stated that Son “may appear up with this kind of a proposal” with regards to Arm but admitted that he has “no plan what that is,” in accordance to statements described by The Korea Herald.

Arm’s chip architecture is behind a lot of of the world’s smartphone processors such as those from Apple and Samsung.

Other organizations have also been touted as becoming fascinated in shopping for a stake in Arm. Cristiano Amon, CEO of U.S. chipmaker Qualcomm, said the company is “an intrigued party in investing” in Arm before this calendar year.

There has also been speculation close to a consortium design with several firms becoming element of a group that invests in Arm.

SoftBank has been underneath pressure to monetize Arm soon after its flagship tech financial commitment business enterprise, the Vision Fund, posted report losses in its final fiscal calendar year. SoftBank marketed the remainder of its overall stake in U.S. trip hailing firm Uber in the next quarter and trimmed its holdings in Chinese e-commerce big Alibaba, to elevate cash.



Supply

Trump’s preferred price for oil is between - based on his social media posts
World

Trump’s preferred price for oil is between $40-$50 based on his social media posts

President Donald Trump has posted more than 200 times about oil prices since he joined Twitter in 2009, with his missives providing some insight on what price he prefers for crude — and it’s not a good level for the U.S. shale industry. Goldman Sachs mined all of Trump’s posts on Twitter, X, and his […]

Read More
Boeing strikes ‘largest-ever’ 787 jet order with Qatar Airways, White House says
World

Boeing strikes ‘largest-ever’ 787 jet order with Qatar Airways, White House says

U.S. President Donald Trump, Qatar’s Emir Tamim bin Hamad Al Thani and Boeing CEO Kelly Ortberg attend a signing ceremony in Doha, Qatar, May 14, 2025. Brian Snyder | Reuters Boeing and GE Aerospace secured a $96 billion agreement to sell Qatar Airways up to 210 aircraft, the White House said Wednesday. The deal for […]

Read More
Why Americans pay so much more for prescription drugs
World

Why Americans pay so much more for prescription drugs

In a photo illustration, prescription drugs are seen next to a pill bottle on July 23, 2024 in New York City. Spencer Platt | Getty Images News | Getty Images President Donald Trump’s latest bid to slash prescription drug prices has once again stirred heated debate about the high costs paid by U.S. patients. The […]

Read More